Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Wobser, M; Voigt, H; Eggert, AO; Houben, R; Kauczok, CS; Brocker, EB; Becker, JC.
Bcl-2 expression in rituximab refractory cutaneous B-cell lymphoma.
Br J Cancer. 2007; 96(10):1540-1543
Doi: 10.1038/sj.bjc.6603762
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Führende Autor*innen der Med Uni Graz
- Becker Jürgen Christian
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Rituximab has been established as an effective and safe therapy for cutaneous B-cell lymphoma (CBCL). Different survival pathways, that is the Raf/MEK/Erk- or the p38MAPK cascade, have been suggested as downstream mediators of rituximab and may be involved in treatment failure. Biopsies from four patients, suffering from different subtypes of CBCL, which were obtained at various time points of relapse during or after therapy with 375 mg rituximab per m2 of body surface area, were analysed for the expression of CD20, CD3, Ki-67, Raf-kinase inhibitory protein (RKIP) and bcl-2 by immunohistochemistry. No CD20-loss variants, that is the suggested main tumour escape mechanism to rituximab therapy, were observed in any specimen of relapsing CBCL. Notably, the expression of proapoptotic RKIP remained increased in these tumour samples. This was concomitated by a constant to slightly reduced proliferation status as demonstrated by Ki-67 staining. However, relapsing CBCL exhibited a strong upregulation of the antiapoptotic molecule bcl-2 in comparison to pretherapeutic levels. The immunohistochemical analyses of this case series of rituximab refractory CBCL suggest that upregulation of bcl-2 may play a major role in therapy resistance.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Antibodies, Monoclonal - therapeutic use
- Antigens, CD20 - genetics
- Antineoplastic Agents - therapeutic use
- Drug Resistance, Neoplasm - genetics
- Female -
- Gene Expression Regulation, Neoplastic -
- Genes, bcl-2 -
- Humans -
- Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - genetics Lymphoma, B-Cell - pathology
- Male -
- Phosphatidylethanolamine Binding Protein - genetics
- Treatment Failure -
- Find related publications in this database (Keywords)
- cutaneous B-cell lymphoma (CBCL)
- rituximab
- RKIP
- bcl-2